[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573095":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":26,"responsibleParty":36,"collaborators":26,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":42,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":26,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":63,"whyStopped":26,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":26},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ASCT group","ACTIVE_COMPARATOR","T-LBL patients achieving CR after induction chemotherapy and then received ASCT as first line consolidation",[13],"Procedure: ASCT",{"label":15,"type":16,"description":17,"interventionNames":18},"Allo-HSCT","EXPERIMENTAL","T-LBL patients achieving CR after induction chemotherapy and received allo-HSCT as first line consolidation",[19],"Procedure: Allo-HSCT",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","ASCT","The chemotherapy-based preconditioning regimen was BeEAM, which consisted of bendamustine (120-180 mg·m-2·day-1，days -8 to -7), etoposide (200 mg·m-2·day-1，days -6 to -3), cytarabine (400 mg·m-2·day-1，days -6 to -3), and melphalan (140 mg·m-2·day-1，days -2).",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Chemotherapy-based preconditioning regimen consisted of cytarabine 4 g·m-2·day-1 (days -9), busulfan (3.2 mg·kg-1·day-1 administered intravenously on days -8 to -6) (day 0 being the first day of donor cell infusion), cyclophosphamide (1.8 g·m-2·day-1, days -5 to -4), and semustine (250 mg.m-2, day -3). For the patients older than 55 years old or with HCT-CI score of 3 or more, cyclophosphamide can be decreased to 1.0 g·m-2·day-1, days -5 to -4, and added fludarabine (30mg·m-2·day-1, days -6 to -2). Rabbit antithymocyte globulin (thymoglobulin, 1.5 to 2.5 mg\u002Fkg, days -5 to -2; Sanofi, France) was administered to the HID and URD groups or MSD HSCT recipients who older than 40 years old (1.5 mg\u002Fkg, days -4 to -2).\n\nAll MSD, HID, and URD HSCT recipinets received cyclosporine A (CsA), mycophenolate mofetil (MMF), and short-term methotrexate (MTX) for GVHD prophylaxis. CsA (2.5 mg\u002Fkg, q12h, intravenous \\[i.v.\\]) was used from day -9, of which the trough concentration was adjusted to 150-250 ng",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Xiao-Dong Mo None","CONTACT","13810096698","moxiaodong@pkuph.edu.cn",{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Xiao-Jun Huang","Investigator","100573095","allo-hsct-vs-asct-in-adult-t-lbl-100573095",false,"NCT06741813","Allo-HSCT vs ASCT in Adult T-LBL","Allogeneic Versus Autologous Hematopoietic Stem Cell Transplantation for Adult T Lymphoblastic Lymphoma as First-line Consolidation.","TROPHY-NHL01","Inclusion Criteria:\n\n* 1\\) Newly diagnosed T-LBL; 2) 18-65 years of age at the time of diagnosis; 3) Categorized into Ann-Arbor stage III or IV; 4) Achieving complete response (CR) after 3 courses of induction chemotherapies; 5) ECOG PS score 0 or 1; 6) It needs consent from the patients or\u002Fand legal guardian, and signature on the Informed Consent.\n\nExclusion Criteria:\n\n* 1\\) Newly diagnosed T-LBL, but categorized into Ann-Arbor stage I or II; 2) \\\u003C 18 years, or older than 65 years at the time of diagnosis; 3) Achieving CR after 4 or more courses of induction chemotherapies, or could not achieve at least CR after induction chemotherapies; 4) with \\> 25% BM involvement or \\> 5% lymphoma cells in the peripheral blood; 5) ECOG PS score of 2 or more; 6) Patients with other comorbidities or mental diseases that influence the life safety and compliance of patients as well as affect informed consent, enrollment in the research, follow-up visit or result interpretation.","ALL","18 Years","65 Years",{"count":52,"type":53},230,"ESTIMATED","INTERVENTIONAL",[56],"NA","Autologous hematopoietic stem cell transplantation (ASCT) is the important consolidation for adult T-LBL. Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is also the important consolidation for adult T-LBL. So ASCT vs allo-HSCT: which is better consolidation for adult T-LBL?",[59],"T Lymphoblastic Lymphoma",[61,62,59],"allogeneic hematopoietic stem cell transplantation","Autologous hematopoietic stem cell transplantation","NOT_YET_RECRUITING","2024-12-15",{"date":66,"type":67},"2024-12-19","ACTUAL",{"date":69,"type":53},"2025-01-01",{"date":71,"type":53},"2029-12-31",{"name":5,"class":6}]